CD8A and neoplasm: Additionally, CCL2 induces the upregulation of programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) in tumor cells and immune cells, and inhibit the activation of CD8+ T cells mediated by PD-1 antibodies.